Abstract:WHAT'S NEW? Extracellular vesicles (EVs) are promising therapeutic tools for cancer, owing to qualities such as immunogenicity and low toxicity. Enhancing the accumulation of EVs in specific cells and tissues, however, requires improved targeting capabilities. In this study, EVs were modified with ephrin‐B2 to explore the effects on targeting and the potential use of EVs specifically against ovarian cancer. Targeting the ephrin‐B4 receptor on ovarian cancer cells significantly improved EV uptake by ovarian cancer cells, both in vitro and in vivo. The engineered EVs maintained their characteristic properties while also exhibiting high targeting efficacy, demonstrating the potential of EVs in cancer therapeutics. Extracellular vesicles (EVs) function as natural mediators of intercellular communication, secreted by cells to facilitate cell–cell signaling. Due to their low toxicity, immunogenicity, biodegradability, and potential to encapsulate therapeutic drugs, EVs hold significant therapeutic promise. Nevertheless, their limited targeting ability often diminishes their therapeutic impact. Therefore, enhancing EVs by incorporating targeting units onto their membranes could bolster their targeting capabilities, enabling them to accumulate in specific cells and tissues. In this study, we engineered EVs to fuse ephrin‐B2 with the EV membrane protein LAMP2b. This modification aimed to direct the engineered EVs toward the ephrin‐B4 receptor expressed on the surface of ovarian cancer cells. The engineered EVs retained their inherent properties, including size, expression of EV membrane proteins, and morphology, upon isolation. In vitro experiments using real‐time imaging revealed that EVs engineered with the ephrin‐B2 ligand exhibited substantial internalization and uptake by ovarian cancer cells, in stark contrast to native EVs. In vivo, the engineered EVs carrying the ephrin‐B2 ligand effectively targeted ovarian cancer cells, surpassing the targeting efficiency of control EVs. This innovative approach establishes a novel targeting system, enhancing the uptake of EVs by ovarian cancer cells. Our findings underscore the potential of using EVs to target cancer cells, thereby enhancing the effectiveness of anti‐cancer therapies while minimizing off‐target effects and toxicity in normal cells and organs.

The Role of Peroxisome Proliferator-Activated Receptor γ in Mediating Cardioprotection Against Ischemia/Reperfusion Injury

Polymeric Nanostructure Compiled with Multifunctional Components to Exert Tumor-Targeted Delivery of Antiangiogenic Gene for Tumor Growth Suppression

An off-the-shelf small extracellular vesicle nanomedicine for tumor targeting therapy

Physio-chemical Modifications to Re-engineer Small Extracellular Vesicles for Targeted Anticancer Therapeutics Delivery and Imaging

Engineering blood exosomes for tumor-targeting efficient gene/chemo combination therapy

Engineered Cancer-Derived Small Extracellular Vesicle-Liposome Hybrid Delivery System for Targeted Treatment of Breast Cancer

Programmable Assembly of Multivalent DNA‐Protein Superstructures for Tumor Imaging and Targeted Therapy

Tumor-microenvironment Responsive Targeted Exosome-like Nanovesicles From Dunaliella Salina for Enhancing Gene/immune Combination Therapy

Targeted therapy using engineered extracellular vesicles: principles and strategies for membrane modification

Extracellular vesicles-hitchhiking boosts the deep penetration of drugs to amplify anti-tumor efficacy

Molecular imaging-guided extracellular vesicle-based drug delivery for precise cancer management: Current status and future perspectives

Synergetic Tumor Probes for Facilitating Therapeutic Delivery by Combined-Functionalized Peptide Ligands

Application of engineered extracellular vesicles for targeted tumor therapy

Engineered mesenchymal stem cell-derived extracellular vesicles constitute a versatile platform for targeted drug delivery

Size and structure of bacterial, fungal and nematode communities along an Antarctic environmental gradient.

Enhancing precision targeting of ovarian cancer tumor cells in vivo through extracellular vesicle engineering

Supramolecular engineering of cell membrane vesicles for cancer immunotherapy

Extracellular vesicles as drug vectors for precise cancer treatment.

Microchip Based Isolation and Drug Delivery of Patient-Derived Extracellular Vesicles Against Their Homologous Tumor

Chemically Edited Exosomes with Dual Ligand Purified by Microfluidic Device for Active Targeted Drug Delivery to Tumor Cells.

Engineered Extracellular Vesicles for Cancer Therapy